31,005 Bristol Myers Squibb Company $BMY Shares Sold by Chiron Capital Management LLC

Key Points

• Chiron Capital Management cut its Bristol Myers Squibb stake by 15%, selling 31,005 shares and retaining 175,965 shares worth approximately $10.98 million. BMY remains the firm’s largest holding and represents about 9.8% of its portfolio.
• Institutional ownership remains high at 76.41%, with major investors including BlackRock and State Street increasing their positions during the reported periods.
• BMY shares traded around $61.15, with a consensus analyst rating of Hold and an average price target of $64.88. The company reported better-than-expected earnings, maintains a quarterly dividend of $0.63 per share, and is advancing late-stage drug programs despite mixed analyst views and long-term patent concerns.

Chiron Capital Management LLC cut its stake in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 15.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 175,965 shares of the biopharmaceutical company's stock after selling 31,005 shares during the quarter. Bristol Myers Squibb accounts for about 9.8% of Chiron Capital Management LLC's investment portfolio, making the stock its largest holding. Chiron Capital Management LLC's holdings in Bristol Myers Squibb were worth $10,980,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. BlackRock Inc. grew its position in Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. State Street Corp raised its stake in Bristol Myers Squibb by 7.3% during the 2nd quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company's stock valued at $6,093,755,000 after buying an additional 7,192,724 shares during the last quarter. Primecap Management Co. CA bought a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Bristol Myers Squibb by 0.5% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company's stock valued at $1,315,984,000 after buying an additional 119,690 shares during the period. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Bristol Myers Squibb by 2.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 18,762,589 shares of the biopharmaceutical company's stock valued at $1,137,847,000 after buying an additional 520,330 shares during the period. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported encouraging Phase 3 data for RYZ101 in advanced gastroenteropancreatic neuroendocrine tumors, including an improvement in progression-free survival. The results could support upcoming regulatory discussions and strengthen the company’s oncology pipeline. What Could Bristol Myers Squibb Two Phase 3 Wins Change?
• Positive Sentiment: Additional late-stage results for admilparant in idiopathic pulmonary fibrosis were described as showing meaningful clinical benefits and a favorable safety profile. If confirmed, the program could add a new growth opportunity beyond Bristol Myers’ established products. Phase 3 Wins
• Positive Sentiment: Truist maintained a Buy rating, while several articles highlighted BMY’s relatively modest valuation, income potential and history of maintaining dividends through difficult market conditions. Its valuation metrics include a P/E near 13.5 and a PEG ratio below 0.3. Truist Buy Rating
• Neutral Sentiment: BMY became a heavily searched or “trending” stock on Zacks, increasing visibility but providing no fundamental change by itself. Analysts’ opinions remain mixed across comparisons with other healthcare companies. Trending Stock Analysis
• Negative Sentiment: Other coverage characterized the admilparant Phase 3 results as mixed, creating uncertainty about the drug’s ultimate approval prospects and commercial contribution. Investors must also weigh long-term patent expirations and competition affecting blockbuster medicines. Mixed Phase 3 Trial Results

Insider Activity at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BMY has been the subject of several research analyst reports. Zacks Research raised Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Wednesday, September 23rd. Leerink Partners cut Bristol Myers Squibb from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $73.00 to $59.00 in a research report on Monday, October 5th. Citigroup restated a "neutral" rating and set a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Truist Financial restated a "buy" rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. Finally, Bank of America reduced their price target on shares of Bristol Myers Squibb from $71.00 to $66.00 in a research report on Friday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $64.88.

Bristol Myers Squibb Stock Performance

Shares of NYSE:BMY traded up $1.87 during midday trading on Thursday, hitting $61.15. The company had a trading volume of 5,578,121 shares, compared to its average volume of 12,057,397. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a fifty day moving average of $63.72 and a two-hundred day moving average of $60.28. The company has a market cap of $124.91 billion, a price-to-earnings ratio of 13.46, a PEG ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.70 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.1%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb's payout ratio is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb's portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.